Business
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China.
About this update from Brii Biosciences Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT","length":213,"tagName":"p"}]},{"val":[{"type":"text","content":"48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the added benefits of elebsiran towards achieving a higher rate of HBsAg loss in combination with PEG-IFNα","length":176,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":389,"olType":false},{"type":"text","content":"DURHAM, N.C. and BEIJING, China, March 30, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China.","length":509,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Brii Biosciences Limited)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Brii Biosciences Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":105,"url":"https://media.zenfs.com/en/prnewswire.com/a19981213a11806c724bc1d308aaae78"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V3nK_VGVGa.vonDXTWY9Ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a19981213a11806c724bc1d308aaae78","width":400,"height":105}},"href":"https://mma.prnewswire.com/media/1690538/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"ENSURE (NCT05970289) is a multicenter, open-label Phase 2 study. Cohorts 1-3 were designed to evaluate the contribution of elebsiran, an investigational small interfering ribonucleic acid (siRNA), in combination with pegylated interferon alpha (PEG-IFNα) in participants with chronic HBV infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU/mL. Participants who completed 9 doses of BRII-179, a recombinant protein-based therapeutic vaccine, in combination with elebsiran (BRII-835) in a previous APAC study BRII-179-835-00...